Balance Sheet
Cash Flow Statement
AmortizationAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for Legend Biotech (LEGN) over the last 6 years, with Q3 2025 value amounting to $15.0 million.

  • Legend Biotech's Share-based Compensation fell 63.53% to $15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.8 million, marking a year-over-year decrease of 465.33%. This contributed to the annual value of $34.3 million for FY2022, which is 7034.43% up from last year.
  • Latest data reveals that Legend Biotech reported Share-based Compensation of $15.0 million as of Q3 2025, which was down 63.53% from $18.7 million recorded in Q2 2025.
  • Legend Biotech's Share-based Compensation's 5-year high stood at $34.3 million during Q4 2022, with a 5-year trough of $2.3 million in Q1 2021.
  • Its 5-year average for Share-based Compensation is $14.8 million, with a median of $15.1 million in 2024.
  • Per our database at Business Quant, Legend Biotech's Share-based Compensation soared by 32348.74% in 2021 and then plummeted by 1474.1% in 2025.
  • Over the past 5 years, Legend Biotech's Share-based Compensation (Quarter) stood at $20.2 million in 2021, then soared by 70.34% to $34.3 million in 2022, then crashed by 63.96% to $12.4 million in 2023, then rose by 22.09% to $15.1 million in 2024, then fell by 0.64% to $15.0 million in 2025.
  • Its Share-based Compensation stands at $15.0 million for Q3 2025, versus $18.7 million for Q2 2025 and $15.9 million for Q1 2025.